p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma

Journal of Clinical Oncology

Volumn 15, Issue 9, 1997, Pages 3111-3120

  Hirvikoski, Pasi ^a   Kumpulainen, Eero ^a   Virtaniemi, Jukka ^a   Johansson, Risto ^a   Haapasalo, Hannu ^a   Marin, Sinikka ^a   Halonen, Pirjo ^a   Helin, Heikki ^a   Raitiola, Hannu ^a   Pukander, Juhani ^a   Kellokumpu Lehtinen, Pirkko ^a   Kosma, Veli Matti ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; FEMALE; HALF LIFE TIME; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MALE; MITOSIS INDEX; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

EID: 0030861888     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.9.3111     Document Type: Article

References (66)

1. Parkin DM, Stjenswärd J, Muir CS: Bull World Health Organ 62:163-182, 1984
2. Sessions RB, Harrison LB, Hong WK: Tumors of the larynx and hypopharynx, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 631-655
3. Austen D: Larynx, in Schottenfield D, Fraumeni J (eds): Cancer Epidemiology and Prevention, Philadelphia, PA WB Saunders, 1982, p 554
4. Pera E, Morena A, Galindo L: Prognostic factors in laryngeal carcinoma. A multifactorial study of 416 cases. Cancer 58:928-934, 1986
5. Chang F, Syrjänen S, Syrjänen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022, 1995
6. Maestro R, Dolcetti R, Gasparotto D, et al: High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 7:1159-1166, 1992
7. Tomasino RM, Morello V, Bazan V, et al: p53 expression in stage III-IV squamous-cell carcinoma of the larynx: An immunohistochemical study related to clinoco-pathological, flow-cytometric DNA analysis and prognosis. Int J Oncol 5:495-500, 1994
8. Ahomadegbe JC, Barrois M, Fogel S, et al: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10:1217-1227, 1995
9. Nadal A, Campo E, Pinto J, et al: p53 expression in normal, dysplastic and neoplastic laryngeal epithelium. Absence of correlation with prognostic factors. J Pathol 175:181-188, 1995
10. Sasano H, Miyazaki, Gooukon Y, et al: Expression of p53 in human esophageal carcinoma: An immunohistochemical study with correlation to proliferating cell nuclear antigen expression. Hum Pathol 23:1238-1243, 1992
11. Haapasalo H, Isola J, Sallinen P, et al: Aberrant p53 expression in astrocytic neoplasms of the brain: Association with proliferation. Am J Pathol 142:1347-1351, 1993
12. Nawa G, Ueda T, Mori S, et al: Prognostic significance of Ki 67 (MIB 1) proliferation index and p53 over-expression in chondrosarcomas. Int J Cancer (Pred Oncol) 69:86-91, 1996
13. Campo E, Calle-Martin O, Miquel R, et al: Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 51:4436-4442, 1991
14. Morkve O, Halvorsen OJ, Stangeland L, et al: Quantitation of biological tumor markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer. Int J Cancer 52:851-855, 1992
15. Nylander K, Stenling R, Gustafsson H, et al: p53 expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 75:87-93, 1995
16. Veronese SM, Gambacorta M, Gottardi O, et al: Proliferation index as a prognostic marker in breast cancer. Cancer 71:3926-3931, 1993
17. Youssef EM, Matsuda T, Takada N, et al: Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 76:358-366, 1995
18. Seshadri R, Leong AS-Y, McCaul K, et al: Relationship between p53 gene abnormalities and other tumor characteristics in breast-cancer prognosis. Int J Cancer 69:135-141, 1996
19. Sallinen PK, Haapasalo HK, Visakorpi T, et al: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275-282, 1994
20. Gee JMW, Douglas-Jones A, Hepburn P, et al: A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. J Pathol 177:285-293, 1995
21. Baas IO, Van Den Berg F, Mulder J-WR, et al: Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol 178:264-267, 1996
22. Saxén E, Teppo L: Finnish Cancer Registry: Twenty-five years of a Nation-Wide Cancer Registry. Helsinki, Finnish Cancer Registry, 1978
23. Karnofsky DA, Abelman WH, Craver LF, et al: The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634-656, 1948
24. Hermanek P, Sobin LH (eds): UICC International Union Against Cancer: TNM classification of malignant tumors, ed 4, rev 2, 1992
25. Haapasalo H, Collan Y, Pesonen E: Volume corrected mitotic index (M/V index) - the standard of mitotic activity in neoplasms. Path Res Pract 185:551-554, 1989
26. Haapasalo H, Collan Y, Montironi R, et al: Consistency of quantitative methods in ovarian tumor histopathology. Int J Gynecol Pathol 9:208-216, 1990
27. Lipponen PK, Kosma V-M, Collan Y, et al: Potential of nuclear morphometry and volume-corrected mitotic index in grading transitional cell carcinoma of the urinary bladder. Eur Urol 17:333-337, 1990
28. Dolcetti R, Doglioni C, Maestro R, et al: p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: Genetic and prognostic implications. Int J Cancer 52:178-182, 1992
29. Anwar K, Nakakuki K, Imai H, et al: Overexpression of p53 protein in human laryngeal carcinoma. Int J Cancer 53:952-956, 1993
30. Nagao T, Kondo F, Sato T, et al: Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining. Hum Pathol 26:326-333, 1995
31. Nishio M, Koshikawa T, Kuroishi T, et al: Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 14:497-502, 1996
32. Pruneri G, Pignataro L, Fracchiolla NS, et al: p53 protein expression in laryngeal squamous cell carcinomas bearing wild-type and mutated p53 gene. Histopathology 28:513-519, 1996
33. Field JK, Malliri A, Butt SA, et al: p53 expression in end-stage squamous cell carcinoma of the head and neck prior to chemotherapy treatment: Expression correlates with a very poor clinical outcome. Int J Oncol 3:431-435, 1993
34. Joypaul BV, Hopwood D, Newman EL, et al: The prognostic significance of the accumulation of p53 tumor-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69:943-946, 1994
35. Klemi J-P, Pylkkänen L, Kiiholma P, et al: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76:1201-1208, 1995
36. Törmänen U, Eerola A-K, Rainio P, et al: Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 55:5595-5602, 1995
37. McLaren R, Kuzu I, Dunnil M, et al: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735-738, 1992
38. Lipponen P, Aaltomaa S, Syrjänen S, et al: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55:51-56, 1993
39. Lee JS, Yoon A, Kalapurakal SK, et al: Expression of p53 oncoprotein in non-small-cell lung cancer: A favourable prognostic factor. J Clin Oncol 13:1893-1903, 1995
40. Passlick B, Izbicki JR, Riethmüller G, et al: p53 in non-small-cell lung cancer. J Natl Cancer Inst 86:801-802, 1994
41. Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898, 1996
42. Servomaa K, Kiuru A, Grénman R, et al: p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Prolif 29:219-230, 1996
43. Wang CC: Radiation therapy for head and neck neoplasms (ed 3), New York, NY, Wiley-Liss, 1996, pp 221-254
44. Levine AJ, Perry ME, Chang A, et al: The 1993 Walter Hubert lecture: The role of p53 tumor suppressor gene in tumorigenesis. Br J Cancer 69:409-416, 1994
45. Cho U, Gorina S, Jeffrey P, et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355, 1994
46. Scheffner M, Werness BA, Huibreigtse JM, et al: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degeneration of p53. Cell 63:1129-1136, 1990
47. Oliner JD, Pietenpol JA, Thiagalingam S, et al: Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362:857-860, 1993
48. Hall PA, Lane DP: p53 in tumour pathology: Can we trust immunohistochemistry? - Revisited! J Pathol 172:1-4, 1994 (editorial)
49. Farmer G, Bargonetti J, Zhu H, et al: Wild-type p53 activates transcription in vitro. Nature 358:83-86, 1992
50. Kern SE, Pietenpol JA, Thiagalingam S, et al: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830, 1992
51. Lowe SW, Schmitt EM, Smith SW, et al: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993
52. Symonds H, Krall L, Remington L, et al: p53-dependent apoptosis suppress tumor growth and progression in vivo. Cell 78:703-711, 1994
53. Lipponen P, Aaltomaa S: Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 173:333-339, 1994
54. Bardeesy N, Beckwith JB, Pelletier J: Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with gene mutations. Cancer Res 55:215-219, 1995
55. Ohbu M, Saegusa M, Okayasu I: Apoptosis and cellular proliferation in oesophageal squamous cell carcinomas: differences between keratinizing and nonkeratinizing types. Virchows Arch 426:271-276, 1995
56. Shoji Y, Saegusa M, Takano Y, et al: Correlation of apoptosis with tumor cell differentiation, progression, and HPV infection in cervical carcinoma. J Clin Pathol 49:134-138, 1996
57. Gorgoulis V, Rassidakis G, Karameris A, et al: Expression of p53 protein in laryngeal squamous cell carcinoma and dysplasia: Possible correlation with human papillomavirus infection and clinicopathological findings. Virch Arch 425:481-489, 1994
58. Tomasino RM, Daniele E, Bazan V, et al: Prognostic significance of cell kinetics in laryngeal squamous cell carcinoma: Clinicopathological associations. Cancer Res 55:6103-6108, 1995
59. Porchen R, Classen S, Piontek M, et al: Vascularization of carcinomas of the esophagus and its correlation with tumor proliferation. Cancer Res 54:587-591, 1994
60. Zätterström UK, Brun E, Willen R, et al: Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head Neck 17:312-318, 1995
61. Weidner N, Moore DH, Vartanian R: Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB-1 antibody. Hum Pathol 25:337-342, 1994
62. Keshgegian AA, Cnaan A: Proliferation markers in breast carcinoma Mitotic figure count. S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104:42-49, 1995
63. Haapasalo H, Collan Y, Atkin NB, et al: Prognosis of ovarian carcinomas: Prediction by histoquantitative methods. Histopathology 15:167-178, 1989
64. Aaltomaa S, Lipponen P, Eskelinen M, et al: Prognostic scores combining clinical, histological and morphometric variables in assessment of the disease outcome in female breast cancer. Int J Cancer 49:886-892, 1991
65. Hall PA, Levison DA: Assessment of cell proliferation in histological material. J Clin Pathol 43:184-192, 1990
66. Linden MD, Torres FX, Kubus J, et al: Clinical application of morphologic and immuno-cytochemical assessments of cell proliferation. Am J Clin Pathol 97:4-13, 1992 (suppl 1)